Safety and Tolerability Study of NBI-98854 for the Treatment of Subjects With Tourette Syndrome
Status:
Completed
Trial end date:
2017-11-01
Target enrollment:
Participant gender:
Summary
Phase 2, open-label, fixed-dose titration study to evaluate the safety and tolerability of
NBI-98854 administered once daily for a total of 24 weeks in children, adolescents, and
adults with Tourette Syndrome (TS).